Baxter (NYSE:BAX) said today that its Evo IQ infusion system won CE Mark clearance and regulatory approval in Australia.
The company plans to start the launch process for its infusion system in the U.K., Ireland, New Zealand and Australia in the third quarter of this year.
Get the full story at our sister site, Drug Delivery Business News.
The post Baxter wins CE Mark for Evo IQ infusion system appeared first on MassDevice.